department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Cyclophosphamide · pharmadog

pharmadog
drugs
Cyclophosphamide

drug

patient view →

cyclophosphamide

Marketedupdated 2mo ago

by Long Grove Pharmaceuticals LLC

Approved

community read0 votes

indications

investigational

Breast CancerDLBCL

all catalysts(3)

phase 1 2 completion · 2

phase 2 initiation · 1

News(0)

no news has mentioned this drug yet

brand

Cyclophosphamide

generic

cyclophosphamide [INN]

indication

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

phase

marketed

phase 1 2 completion

General Hospital of the People's Liberation Army — cyclophosphamide (Phase I/II Trial Completion)

cyclophosphamide

phase 1 2 completion

Institute of Hematology & Blood Diseases Hospital — cyclophosphamide (Phase I/II Trial Completion)

cyclophosphamide

phase 2 initiation

National Cancer Institute US — cyclophosphamide (Phase II Trial Initiation)

cyclophosphamide

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Jun 26, 2035

~9.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (15)

Feb 15, 2036formulationUS 10993952
Feb 15, 2036formulationUS 10993952
Feb 15, 2036formulationUS 10993952
Feb 15, 2036formulationUS 12329767
Feb 15, 2036formulationUS 12329767
Feb 15, 2036formulationUS 12329767
Dec 1, 2035formulationUS 11382923
Dec 1, 2035formulationUS 11382923
Dec 1, 2035formulationUS 11382923
Jul 13, 2035formulationUS 10849916
Jul 13, 2035formulationUS 10849916
Jul 13, 2035formulationUS 10849916
Jun 26, 2035formulationUS 9662342
Jun 26, 2035formulationUS 9662342
Jun 26, 2035formulationUS 9662342

🐶 often sniffed alongside

top 8

tagDLBCL6 co-mentions · 3 sources
tagOncology5 co-mentions · 4 sources
tagCLL4 co-mentions · 1 sources
companySandoz Inc2 co-mentions · 1 sources
tagHematology2 co-mentions · 1 sources
companyCity of Hope1 co-mentions · 1 sources
companyNational Cancer Institute US1 co-mentions · 1 sources
companyGeneral Hospital of the People's Liberation Army1 co-mentions · 1 sources

Trials studying cyclophosphamide

phase3A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)recruitingn=960
phase2Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemiarecruitingn=30
phase1Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myelomacompletedn=3
phase1A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseasesrecruitingn=52
phase2Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Caactive not recruitingn=46
phase1ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignanciescompletedn=16
phase1A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Diseaserecruitingn=66
EP1Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.recruitingn=20

more trials →